Status:

COMPLETED

Methylphenidate to Improve Balance and Walking in MS

Lead Sponsor:

Oregon Health and Science University

Collaborating Sponsors:

Portland VA Medical Center

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

20-65 years

Phase:

PHASE2

PHASE3

Brief Summary

Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and...

Detailed Description

The proposed pilot study will examine the effects of methylphenidate on imbalance and walking in 24 subjects with MS and imbalance. The subjects will be randomly assigned to receive either an escalati...

Eligibility Criteria

Inclusion

  • Age 20-65
  • Able to walk at least 100m without an aide or with unilateral assistance
  • Poor static balance, specifically prolonged APR latencies (≥ 1 standard deviation (SD) \> mean for healthy people in this age range), OR
  • Reduced balance-related activity (ABC scores ≤ 85%)
  • Walking difficulties, specifically T25FW \> 6 seconds, OR reduced self perceived walking (MSWS-12 scores ≥ 50/60)

Exclusion

  • Currently taking methylphenidate, modafinil, or armodafinil.(any within the last 2 weeks)
  • Cause(s) of imbalance other than MS
  • Systolic pressure consistently greater than 150 mm Hg or diastolic pressure consistently greater than 90 mm Hg
  • Contraindications to methylphenidate (Anxiety, tension, agitation, thyrotoxicosis, tachyarrhythmias, severe angina pectoris or glaucoma, hypersensitivity to methylphenidate, motor tics or a family history or diagnosis of Tourette's syndrome, seizures, severe or poorly controlled hypertension, treatment with monoamine oxidase inhibitors currently or within the last 14 days, current use of guanethidine, pressors, coumarin anticoagulants, anticonvulsants, phenylbutazone, or tricyclic antidepressants, history of drug abuse or alcoholism)
  • Pregnancy or breastfeeding

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2016

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01896700

Start Date

July 1 2013

End Date

April 1 2016

Last Update

April 5 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Portland VA Medical Center

Portland, Oregon, United States, 97239